Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Hookipa Biotech AG
DescriptionBivalent vaccine against CMV that uses Vaxwave technology vectors to express CMV pp65 (UL83) and truncated CMV glycoprotein B
Molecular Target Human cytomegalovirus (CMV) phosphoprotein 65 (pp65) (UL83) ; Human cytomegalovirus (CMV) glycoprotein B
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationCytomegalovirus (CMV)
Indication DetailsVaccine against CMV infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today